Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Abbott enters into agreement with FDA, outlining terms for resuming infant formula production at Michigan site

CHICAGO — Abbott Laboratories and the U.S. Food and Drug Administration have come to an agreement on the steps the company needs to take before it can restart production of infant formula at a Michigan facility, Abbott said Monday.

Chicago Tribune

Abbott Spent $5B On Stock Buybacks Instead Of Fixing Its Baby Formula Factory

The fear of not knowing where your child’s next meal comes from is something that no parent should face. But, because of a recall of Abbott Laboratories’ (NYSE: ABT) Similac and other popular baby formula brands, stores throughout the nation are limiting how much formula parents can buy.

Benzinga

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Are Akebia Therapeutics Shares Falling Today?

Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.…

Benzinga

Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients

Sanofi SA (NASDAQ:SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy. Sarclisa combined with carfilzomib and dexamethasone (Kd) demonstrated a median progression-free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone. …

Benzinga

FDA Warns About THC Copycat Edibles, Children In Serious Danger

About a month after a study led by researchers at NYU School of Global Public Health, revealed that “copycat” edibles can have levels of tetrahydrocannabinol or THC “that

Benzinga

FDA chief says shuttered baby formula plant could reopen soon, offering hope to ease shortage

The head of the Food and Drug Administration said Monday that a shuttered baby formula factory should reopen within two weeks, potentially easing a serious nationwide shortage.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial

Magenta Therapeutics Inc (NASDAQ:MGTA) shared preliminary data from the Phase 1/2 dose-escalation trial of MGTA-117 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts. The data comes from a Cohort 1, evaluating the lowest dose of MGTA-117 (0.02 mg/kg). Three patients completed the safety evaluation period. A fourth patient with…

Benzinga

41 Stocks Moving In Monday's Mid-Day Session

Gainers Data Storage Corporation (NASDAQ: DTST) shares jumped 51.1% to $3.4750 after the company reported better-than-expected Q1 financial results.

Benzinga

scPharmaceuticals Shares Are Trading High Following FDA's Acceptance of NDA for FUROSCIX

scPharmaceuticals Inc. (NASDAQ: SCPH) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of the drug candidate FUROSCIX, for the treatment of congestion in patients with worsening heart failure.

Benzinga

FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of IgA nephropathy (IgAN).

Benzinga

Biden offers logistics support to ease formula shortage

President Joe Biden is offering formula manufacturers and retailers transportation and logistics support to ease the nationwide shortage of baby formula

The Independent UK

Here's Why Travere Therapeutics Shares Are Rising Today

Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy.

Benzinga

Buffalo Shooting Will Prompt Measures 'To Combat Domestic Terrorism,' Says Pelosi

Plus: Netflix defends artistic expression, perspectives on the baby formula shortage, and more...

Reason

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president…

Benzinga

Why Eli Lilly Shares Are Trading Higher Today

The FDA approved Eli Lilly And Co's (NYSE:LLY) injected drug tirzepatide, which has the brand name Mounjaro (tirzepatide), to help improve blood sugar control in adults with type 2 diabetes. The approval covers tirzepatide as an adjunct to diet and exercise. As the first and only FDA-approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1…

Reason

Anti-Vaping Hysteria Is Deadly

We're repeating the mistakes of the war on drugs.

Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, May 16

CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

Vapers warned they 'are inhaling potentially dangerous levels of synthetic chemicals'

Little is known about the content of synthetic coolants in e-cigarettes or their health risks

The Independent UK

Bette Midler faces backlash for telling mothers to ‘try breastfeeding’ their babies amid formula shortage

‘What a profoundly offensive and ignorant statement’

Tribune News Service

Baby-formula shortage spurs US to prod Abbott over access

WASHINGTON — The Biden administration on Friday urged Abbott Laboratories to do more to ensure low-income families on federal assistance have access to baby formula, amid a nationwide shortage.

WEKU

White House bolsters efforts to get baby formula into the hands of WIC recipients

States have been asked to increase accessibility of baby formula for recipients of the low-income program. And the Food and Drug Administration is looking at ways to make it easier to import formula.

Axios

Why there is a baby formula crisis and what can be done about it

The formula shortage may continue for months.

Chicago Tribune

After baby formula recall, Abbott says it can restart production at Michigan site within 2 weeks of FDA approval

Abbott Laboratories said it could have some of its recalled infant formulas back on store shelves within eight to 10 weeks after the U.S. Food and Drug Administration gives its approval, though it’s unclear when that approval may come.

Reuters

Imported infant formula could help lift U.S. supply in weeks -FDA chief

The Food and Drug Administration will outline a plan next week to streamline imports of infant formula, the agency's chief said on Friday, adding that the action along with others would "help dramatically improve the supply in the U.S. in a matter of weeks."

1 … 228 229 230 231

People

Elizabeth Nolan Brown

41 stories

Stephanie Ruhle

34 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.